
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11329535/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Logistic Regression in Clinical Studies. International Journal of Radiation Oncology Biology Physics, 2022, 112, 271-277.	0.8	30
2	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. Oncologist, 2022, 27, 380-388.	3.7	12
3	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. European Urology, 2022, 81, 570-573.	1.9	22
4	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. Npj Breast Cancer, 2022, 8, 37.	5.2	9
5	Vulnerabilities in workplace features for essential workers with breast cancer: Implications for the COVID-19 pandemic. Work, 2022, 71, 815-823.	1.1	2
6	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/â^' trastuzumab in patients with breast cancer brain metastases. Npj Breast Cancer, 2022, 8, 50.	5.2	17
7	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. Journal of Clinical Oncology, 2022, 40, 2546-2556.	1.6	292
8	Predictors of operative difficulty in robotic low anterior resection for rectal cancer. Colorectal Disease, 2022, 24, 1318-1324.	1.4	2
9	Lymphedema therapy referral is associated with improved understanding of lymphedema prevention among breast cancer survivors Journal of Clinical Oncology, 2022, 40, 12069-12069.	1.6	0
10	Primary Tumor-Related Complications and Salvage Outcomes in Patients with Metastatic Rectal Cancer and an Untreated Primary Tumor. Diseases of the Colon and Rectum, 2021, 64, 45-52.	1.3	7
11	Comparative analysis of the Memorial Sloan Kettering Bowel Function Instrument and the Low Anterior Resection Syndrome Questionnaire for assessment of bowel dysfunction in rectal cancer patients after low anterior resection. Colorectal Disease, 2021, 23, 451-460.	1.4	16
12	Interpreting the RAPIDO trial: factors to consider. Lancet Oncology, The, 2021, 22, e87-e88.	10.7	1
13	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. Oncologist, 2021, 26, 483-491.	3.7	8
14	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 2910-2919.	7.0	45
15	Endoscopic Feature and Response Reproducibility in Tumor Assessment after Neoadjuvant Therapy for Rectal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 5205-5223.	1.5	11
16	A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <i>PIK3CA</i> -Mutated HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3867-3875.	7.0	15
17	PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays. American Journal of Surgical Pathology, 2021, 45, 1274-1281.	3.7	6
18	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer, 2021, 127, 3946-3956.	4.1	12

#	Article	IF	CITATIONS
19	Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy. Diseases of the Colon and Rectum, 2021, 64, 1463-1470.	1.3	22
20	Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 432-438.	4.9	19
21	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. European Urology Oncology, 2021, 4, 993-1000.	5.4	16
22	Comparing outcomes of robotic <i>versus</i> open mesorectal excision for rectal cancer. BJS Open, 2021, 5, .	1.7	6
23	In silico modeling of combination systemic therapy for advanced renal cell carcinoma. , 2021, 9, e004059.		5
24	Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell car cell renal cell carcinoma: a cohort study. Lancet Oncology, The, 2020, 21, 283-293.	10.7	121
25	Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients. Annals of Surgical Oncology, 2020, 27, 1617-1624.	1.5	20
26	Early Trastuzumab Interruption and Recurrence-Free Survival in <i>ERBB2</i> -Positive Breast Cancer. JAMA Oncology, 2020, 6, 1971.	7.1	20
27	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. Oncolmmunology, 2020, 9, 1841948.	4.6	3
28	Use of patient-reported controls for secular trends to study disparities in cancer-related job loss. Journal of Cancer Survivorship, 2020, 15, 685-695.	2.9	1
29	Everolimus plus bevacizumab is an effective firstâ€line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer, 2020, 126, 5247-5255.	4.1	22
30	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. Journal of Clinical Oncology, 2020, 38, 1332-1337.	1.6	11
31	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. Modern Pathology, 2020, 33, 2221-2232.	5.5	23
32	Patient-Reported Bowel Function in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy After Neoadjuvant Therapy: A Case–Control Study. Diseases of the Colon and Rectum, 2020, 63, 897-902.	1.3	41
33	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
34	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. BMC Urology, 2020, 20, 84.	1.4	12
35	The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction. Nature Communications, 2020, 11, 319.	12.8	46
36	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer, 2020, 1, 382-393.	13.2	96

#	Article	IF	CITATIONS
37	Intracorporeal Anastomoses in Minimally Invasive Right Colectomies Are Associated With Fewer Incisional Hernias and Shorter Length of Stay. Diseases of the Colon and Rectum, 2020, 63, 685-692.	1.3	40
38	Effect of Acupuncture vs Sham Procedure on Chemotherapy-Induced Peripheral Neuropathy Symptoms. JAMA Network Open, 2020, 3, e200681.	5.9	54
39	Measuring Tumor Epichaperome Expression Using [¹²⁴ I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. JCO Precision Oncology, 2020, 4, 1414-1424.	3.0	13
40	Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. Oncologist, 2019, 24, e646-e652.	3.7	5
41	A rectal cancer organoid platform to study individual responses to chemoradiation. Nature Medicine, 2019, 25, 1607-1614.	30.7	320
42	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. Clinical Genitourinary Cancer, 2019, 17, 268-274.e1.	1.9	29
43	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. Journal of Clinical Oncology, 2019, 37, 2329-2337.	1.6	17
44	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Research and Treatment, 2019, 177, 61-66.	2.5	42
45	Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases. Clinical Cancer Research, 2019, 25, 3784-3792.	7.0	41
46	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. Clinical Genitourinary Cancer, 2019, 17, e678-e688.	1.9	41
47	Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation. Journal of Gastrointestinal Surgery, 2019, 23, 794-799.	1.7	2
48	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. JAMA Network Open, 2019, 2, e1916211.	5.9	7
49	Comprehensive Genomic Analysis of Metastatic Non–Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. JCO Precision Oncology, 2019, 3, 1-18.	3.0	7
50	Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal Excision. Journal of Gastrointestinal Surgery, 2019, 23, 800-807.	1.7	21
51	Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection. Clinical Breast Cancer, 2018, 18, 353-361.	2.4	16
52	Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. Clinical Breast Cancer, 2018, 18, 387-394.	2.4	37
53	Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy. Annals of Surgical Oncology, 2018, 25, 1912-1920.	1.5	37
54	Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ. Cancer, 2018, 124, 46-54.	4.1	37

#	Article	IF	CITATIONS
55	Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. Diseases of the Colon and Rectum, 2018, 61, 1146-1155.	1.3	115
56	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology, 2018, 4, 1228.	7.1	132
57	Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?. Annals of Surgical Oncology, 2017, 24, 1492-1498.	1.5	47
58	Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. Journal of Bone Oncology, 2017, 7, 32-37.	2.4	21
59	Women With Breast Cancer Who Work For Accommodating Employers More Likely To Retain Jobs After Treatment. Health Affairs, 2017, 36, 274-281.	5.2	75
60	Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. Oncologist, 2017, 22, 139-143.	3.7	27
61	Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer. Annals of Surgical Oncology, 2017, 24, 2182-2188.	1.5	30
62	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. Clinical Genitourinary Cancer, 2017, 15, e987-e994.	1.9	39
63	Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2017, 24, 2556-2562.	1.5	45
64	Work Experiences of Patients Receiving Palliative Care at a Comprehensive Cancer Center: Exploratory Analysis. Journal of Palliative Medicine, 2017, 20, 770-773.	1.1	10
65	Are there patients with T1 to T2, lymph nodeâ€negative breast cancer who are "highâ€risk†for locoregional disease recurrence?. Cancer, 2017, 123, 2626-2633.	4.1	16
66	Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2017, 97, 924-930.	0.8	10
67	Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy. Annals of Surgical Oncology, 2017, 24, 3888-3895.	1.5	13
68	Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?. Annals of Surgical Oncology, 2017, 24, 2889-2897.	1.5	28
69	Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers. Annals of Surgery, 2017, 266, 457-462.	4.2	90
70	Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical followâ€up. Cancer, 2017, 123, 131-137.	4.1	16
71	Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. Clinical Breast Cancer, 2017, 17, 23-28.	2.4	91
72	A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast Cancer Research, 2017, 19, 89.	5.0	45

SUJATA PATIL

#	Article	IF	CITATIONS
73	A Randomized Prospective Comparison of Patientâ€Assessed Satisfaction and Clinical Outcomes with Radioactive Seed Localization versus Wire Localization. Breast Journal, 2016, 22, 151-157.	1.0	65
74	Twentyâ€one–gene recurrence score assay in <scp><i>BRCA</i></scp> â€associated versus sporadic breast cancers: Differences based on germline mutation status. Cancer, 2016, 122, 1178-1184.	4.1	42
75	KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. Annals of Surgical Oncology, 2016, 23, 2548-2555.	1.5	70
76	Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Oncologist, 2016, 21, 418-424.	3.7	46
77	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. Journal of Clinical Oncology, 2016, 34, 2478-2483.	1.6	31
78	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Annals of Surgical Oncology, 2016, 23, 3467-3474.	1.5	232
79	Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Annals of Surgical Oncology, 2016, 23, 2816-2824.	1.5	38
80	Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2016, 23, 3481-3486.	1.5	25
81	Long–Term Renal Outcomes after Cisplatin Treatment. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1173-1179.	4.5	155
82	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non–Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2016, 34, 3846-3853.	1.6	69
83	The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature, 2016, 538, 397-401.	27.8	233
84	Quantitative apparent diffusion coefficient measurement obtained by 3.0Tesla MRI as a potential noninvasive marker of tumor aggressiveness in breast cancer. European Journal of Radiology, 2016, 85, 1651-1658.	2.6	42
85	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Cancer Immunology Research, 2016, 4, 835-844.	3.4	138
86	Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer. Clinical Breast Cancer, 2016, 16, 487-493.	2.4	13
87	Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?. Annals of Surgical Oncology, 2016, 23, 4253-4261.	1.5	40
88	Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7) Tj ETQq0 0 C) rgBT /Ov	erlgck 10 Tf 5
89	A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. Oncologist, 2016, 21, 787-788d.	3.7	84

90 Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. Clinical Genitourinary Cancer, 2016, 14, 56-62.

1.9 7

SUJATA PATIL

#	Article	IF	CITATIONS
91	Is Preoperative Axillary Imaging Beneficial in Identifying Clinically Node-Negative Patients Requiring Axillary Lymph Node Dissection?. Journal of the American College of Surgeons, 2016, 222, 138-145.	0.5	68
92	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer, 2016, 16, 87-94.	2.4	1
93	Fertility Preservation for the Young Breast Cancer Patient. Annals of Surgical Oncology, 2016, 23, 1530-1536.	1.5	35
94	Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. Clinical Breast Cancer, 2016, 16, 276-283.	2.4	11
95	Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer. Annals of Surgical Oncology, 2016, 23, 471-476.	1.5	13
96	Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ. Annals of Surgery, 2015, 262, 623-631.	4.2	94
97	Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2015, 33, 442-447.	1.6	75
98	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, andÂCarboplatin (TI-TIC) With Autologous StemÂCell Reinfusion for Salvage Treatment ofÂGerm Cell Tumors. Clinical Genitourinary Cancer, 2015, 13, 453-460.	1.9	5
99	Development of a risk stratification system to guide treatment for female germ cell tumors. Gynecologic Oncology, 2015, 138, 566-572.	1.4	34
100	Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncology, The, 2015, 16, 957-966.	10.7	524
101	Does Endoscopic Ultrasound Improve Detection of Locally Recurrent Anal Squamous-Cell Cancer?. Diseases of the Colon and Rectum, 2015, 58, 193-198.	1.3	7
102	Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Annals of Surgical Oncology, 2015, 22, 3273-3281.	1.5	46
103	Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. Journal of Clinical Oncology, 2015, 33, 3945-3952.	1.6	153
104	Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis. Clinical Genitourinary Cancer, 2015, 13, 59-66.	1.9	32
105	Recurrence rates for ductal carcinoma in situ: Analysis of 2,996 patients treated with breast-conserving surgery over 30 years Journal of Clinical Oncology, 2015, 33, 32-32.	1.6	1
106	Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. PLoS ONE, 2014, 9, e114900.	2.5	77
107	Local Relapse After Breast-Conserving Therapy for Ductal Carcinoma In Situ. Cancer Journal (Sudbury,) Tj ETQq1	1 0.78431 2.0	4 rgBT /Ove
108	Perioperative Breast MRI Is Not Associated with Lower Locoregional Recurrence Rates in DCIS Patients Treated With or Without Radiation. Annals of Surgical Oncology, 2014, 21, 1552-1560.	1.5	50

#	Article	IF	CITATIONS
109	Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy. Annals of Surgical Oncology, 2014, 21, 22-27.	1.5	99
110	A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. Clinical Breast Cancer, 2014, 14, 154-160.	2.4	91
111	Intravoxel incoherent motion diffusionâ€weighted MRI at 3.0 T differentiates malignant breast lesions from benign lesions and breast parenchyma. Journal of Magnetic Resonance Imaging, 2014, 40, 813-823.	3.4	95
112	Brain metastases in breast cancer. Expert Review of Anticancer Therapy, 2014, 14, 173-183.	2.4	8
113	Estrogen Receptor, Progesterone Receptor, and HER2 Status Predict Lymphovascular Invasion and Lymph Node Involvement. Annals of Surgical Oncology, 2014, 21, 3780-3786.	1.5	71
114	Early predictors of not returning to work in low-income breast cancer survivors: a 5-year longitudinal study. Breast Cancer Research and Treatment, 2013, 140, 407-416.	2.5	56
115	Is there a role for routine screening MRI in women with LCIS?. Breast Cancer Research and Treatment, 2013, 142, 445-453.	2.5	53
116	Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2013, 11, 297-302.	1.9	46
117	Should Breast Density Influence Patient Selection for Breast-Conserving Surgery?. Annals of Surgical Oncology, 2013, 20, 600-606.	1.5	17
118	Blurry Boundaries: Do Epithelial Borderline Lesions of the Breast and Ductal Carcinoma In Situ Have Similar Rates of Subsequent Invasive Cancer?. Annals of Surgical Oncology, 2013, 20, 1302-1310.	1.5	7
119	Selection Criteria for Postmastectomy Radiotherapy in T1–T2 Tumors with 1 to 3 Positive Lymph Nodes. Annals of Surgical Oncology, 2013, 20, 3169-3174.	1.5	77
120	Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Medicine, 2013, 2, 725-733.	2.8	54
121	Clinical features, presentation, and tolerance of platinumâ€based chemotherapy in germ cell tumor patients 50 years of age and older. Cancer, 2013, 119, 2574-2581.	4.1	30
122	Longâ€ŧerm cardiac safety and outcomes of doseâ€dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer, 2013, 119, 3943-3951.	4.1	18
123	Radiation therapy for breast cancer (BC) with central nervous system (CNS) metastases: A contemporary experience at Memorial Sloan-Kettering Cancer Center (MSKCC) Journal of Clinical Oncology, 2013, 31, 144-144.	1.6	1
124	Validation of a Nomogram for Predicting Risk of Local Recurrence for Ductal Carcinoma In Situ. Journal of Clinical Oncology, 2012, 30, 3143-3144.	1.6	7
125	Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer, 2012, 118, 5454-5462.	4.1	55
126	Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. Breast Cancer Research and Treatment, 2012, 135, 93-102.	2.5	34

#	Article	IF	CITATIONS
127	Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer. Clinical Cancer Research, 2012, 18, 6784-6791.	7.0	176
128	Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. Breast Journal, 2012, 18, 345-350.	1.0	29
129	Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer, 2012, 118, 1868-1876.	4.1	109
130	Adjuvant trastuzumab reduces locoregional recurrence in women who receive breastâ€conservation therapy for lymph nodeâ€negative, human epidermal growth factor receptor 2â€positive breast cancer. Cancer, 2012, 118, 1982-1988.	4.1	80
131	Progressionâ€free and overall survival in patients with relapsed/refractory germ cell tumors treated with singleâ€agent chemotherapy: Endpoints for clinical trial design. Cancer, 2012, 118, 981-986.	4.1	50
132	Return to work in lowâ€income Latina and nonâ€Latina white breast cancer survivors: A 3â€year longitudinal study. Cancer, 2012, 118, 1664-1674.	4.1	81
133	Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 131, 111-116.	2.5	21
134	Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Investigational New Drugs, 2012, 30, 335-340.	2.6	79
135	Biomarkers that predict sensitivity to heat shock protein 90 inhibitors (HSP90i) Journal of Clinical Oncology, 2012, 30, 10618-10618.	1.6	3
136	Sarcomatoid-variant Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 454-459.	1.3	91
137	PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Research and Treatment, 2011, 129, 635-643.	2.5	49
138	Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer, 2011, 117, 4125-4131.	4.1	16
139	Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer, 2011, 117, 5461-5468.	4.1	77
140	Reply to S. Stenning et al and J. Lipshitz. Journal of Clinical Oncology, 2011, 29, 4211-4212.	1.6	0
141	Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib. Clinical Cancer Research, 2011, 17, 3490-3499.	7.0	131
142	HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clinical Cancer Research, 2011, 17, 5132-5139.	7.0	396
143	Carboplatin in Clinical Stage I Seminoma: Too Much and Too Little at the Same Time. Journal of Clinical Oncology, 2011, 29, 949-952.	1.6	23
144	Reply to C. Mazouni et al. Journal of Clinical Oncology, 2011, 29, e45-e46.	1.6	2

#	Article	IF	CITATIONS
145	Targeted Oligonucleotide Array Assessment of Genomic Copy Number Alterations for Risk Stratification in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1773-1773.	1.4	0
146	The Influence of Margin Width and Volume of Disease Near Margin on Benefit of Radiation Therapy for Women With DCIS Treated With Breast-Conserving Therapy. Annals of Surgery, 2010, 251, 583-591.	4.2	40
147	Impact of Breast Density on the Presenting Features of Malignancy. Annals of Surgical Oncology, 2010, 17, 211-218.	1.5	141
148	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Investigational New Drugs, 2010, 28, 523-528.	2.6	66
149	Stage migration and increasing proportion of favorableâ€prognosis metastatic renal cell carcinoma patients. Cancer, 2010, 116, 347-354.	4.1	46
150	Integrated Positron Emission Tomography/Computed Tomography May Render Bone Scintigraphy Unnecessary to Investigate Suspected Metastatic Breast Cancer. Journal of Clinical Oncology, 2010, 28, 3154-3159.	1.6	121
151	TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis. Journal of Clinical Oncology, 2010, 28, 1706-1713.	1.6	192
152	Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/ <i>neu</i> –Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea. Journal of Clinical Oncology, 2010, 28, 2982-2988.	1.6	40
153	Nomogram for Predicting the Risk of Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ. Journal of Clinical Oncology, 2010, 28, 3762-3769.	1.6	283
154	PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. Clinical Cancer Research, 2009, 15, 5049-5059.	7.0	338
155	Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2009, 27, 1432-1439.	1.6	298
156	Distress in Older Patients With Cancer. Journal of Clinical Oncology, 2009, 27, 4346-4351.	1.6	116
157	Identification and Validation of a Gene Expression Signature That Predicts Outcome in Adult Men With Germ Cell Tumors. Journal of Clinical Oncology, 2009, 27, 5240-5247.	1.6	70
158	Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breastâ€conserving therapy. Cancer, 2009, 115, 1203-1214.	4.1	19
159	Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. Journal of Clinical Oncology, 2009, 27, 3379-3384.	1.6	370
160	Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome. Diseases of the Colon and Rectum, 2008, 51, 147-153.	1.3	100
161	Phase II Trial of Pegylated Interferon-α2b in Patients with Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2008, 6, 25-30.	1.9	20
162	Infectious Complications from High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Metastatic Germ Cell Tumors. Biology of Blood and Marrow Transplantation, 2008, 14, 595-600.	2.0	6

SUJATA PATIL

#	Article	IF	CITATIONS
163	Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1797-1802.	1.6	60
164	Identifying Vulnerable Older Adults with Cancer: Integrating Geriatric Assessment into Oncology Practice. Journal of the American Geriatrics Society, 2007, 55, 1604-1608.	2.6	131
165	Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Investigational New Drugs, 2007, 25, 487-490.	2.6	21